Activating alleles of JAK3 in acute megakaryoblastic leukemia.
暂无分享,去创建一个
Sandra A. Moore | T. Boggon | J. Nardone | B. Druker | M. Heinrich | M. Deininger | L. McGreevey | D. Gilliland | T. Gu | J. Tyner | M. Loriaux | R. Polakiewicz | V. Goss | T. O'hare | Kimberly A. Lee | T. Mercher | J. Crispino | Brian J Druker | Julie Nardone | D Gary Gilliland | Roberto D Polakiewicz | C. Eide | M. Wong | Michael C Heinrich | Thomas O'Hare | Jeffrey W Tyner | Michael W Deininger | Titus J Boggon | Thomas Mercher | Ting-Lei Gu | D. Walters | Christopher A Eide | Matthew J Wong | Marc Loriaux | Kimberly A Lee | Denise K Walters | Eric P Stoffregen | Laura McGreevey | Valerie L Goss | Sandra A Moore | John Crispino | E. Stoffregen | Laura S. McGreevey
[1] J. Radich,et al. The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.
[2] S. Ziegler,et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. , 1993, Science.
[3] Kimberly Lee,et al. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. , 2006, Leukemia research.
[4] J. O’Shea,et al. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. , 2004, Trends in molecular medicine.
[5] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[6] J. Rush,et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.
[7] J. Ihle,et al. A Kinase-deficient Splice Variant of the Human JAK3 Is Expressed in Hematopoietic and Epithelial Cancer Cells (*) , 1995, The Journal of Biological Chemistry.
[8] S. Orkin,et al. Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.
[9] A. Sharpe,et al. Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3 , 1995, Science.
[10] J. Johnston,et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. , 1994, Science.
[11] T. Boggon,et al. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.
[12] M. Heinrich,et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] Z. Nagy,et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. , 2002, Blood.
[14] Y. Minami,et al. Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[15] L. Notarangelo,et al. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs , 2005, Immunological reviews.
[16] D. Oscier,et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.
[17] F. Uckun,et al. Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis* , 1999, The Journal of Biological Chemistry.
[18] E. Vellenga,et al. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts , 2000, Leukemia.
[19] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[20] P. Doherty,et al. Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.
[21] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[22] R. Berger,et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. , 2000, Blood.
[23] O. Silvennoinen,et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.
[24] Michael P. Brown,et al. Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. , 1999, Blood.
[25] E. Liu,et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells , 1994, Nature.
[26] T. Hirano,et al. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT , 1997, Oncogene.
[27] J. Gustafsson,et al. In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2 , 1998, Molecular and Cellular Endocrinology.
[28] J. Johnston,et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2 , 1994, Nature.
[29] O. Silvennoinen,et al. The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction* , 2002, The Journal of Biological Chemistry.
[30] J. O’Shea,et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.
[31] M. L. Beau,et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.
[32] Blake Middleton,et al. Infectious Th1 and Th2 autoimmunity in diabetes‐prone mice , 1998, Immunological reviews.
[33] J. Johnston,et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. , 1995, Journal of immunology.
[34] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[35] Andrew D. Yates,et al. Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.
[36] S. Meshinchi,et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.
[37] Manuel C. Peitsch,et al. SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..
[38] M. Nerenberg,et al. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. , 1995, The Journal of clinical investigation.
[39] L. Notarangelo,et al. Complex Effects of Naturally Occurring Mutations in the JAK3 Pseudokinase Domain: Evidence for Interactions between the Kinase and Pseudokinase Domains , 2000, Molecular and Cellular Biology.
[40] Stephen K Burley,et al. A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[41] T. Naoe,et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.
[42] J. O’Shea,et al. A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.
[43] S. Constantinescu,et al. JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation , 2005, Journal of Biological Chemistry.
[44] W. Leonard,et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.
[45] Qingshan Li,et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.
[46] D. Small,et al. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.
[47] M. Mann,et al. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.
[48] M. Paul,et al. Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.
[49] T. Naoe,et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.
[50] Y. Hayashi,et al. Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia , 1989, British journal of haematology.
[51] M. Cetkovic-Cvrlje,et al. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. , 2004, Current pharmaceutical design.
[52] K. Liedl,et al. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. , 2001, Protein engineering.
[53] S. Hubbard,et al. Mechanism-based design of a protein kinase inhibitor , 2001, Nature Structural Biology.
[54] R. Levine,et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.
[55] I. Weissman,et al. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. , 2002, The Journal of clinical investigation.
[56] B. Druker,et al. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. , 2005, Blood.
[57] Joshua E. Elias,et al. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. , 2003, Journal of proteome research.
[58] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[59] B. Hall,et al. Cells mediating allograft rejection. , 1991, Immunological reviews.
[60] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[61] F. Uckun,et al. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. , 2003, Clinical immunology.
[62] M. Vihinen,et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency , 2001, Human mutation.
[63] T. Naoe,et al. Differential constitutive activation between STAT‐related proteins and MAP kinase in primary acute myelogenous leukaemia , 1998, British journal of haematology.
[64] R. Perlmutter,et al. Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. , 1998, Journal of immunology.
[65] Eugene C. Petrella,et al. The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine , 2004, Journal of Biological Chemistry.
[66] J. Aster,et al. Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.